Authors' recommendations: No consistent benefit of rFVIIa therapy was detected among studies evaluating the prevention of bleeding in patients undergoing prostatectomy, liver transplantation, or cardiac surgery. The riskof adverse events after the prophylactic use of rFVIIa in surgical patients is unknown. No conclusions can be drawn on the effectiveness or safety of using rFVIIa in the prevention of bleeding in patients who have received supra-therapeutic doses of anticoagulant agents. When used for prevention of bleeding, no specific method is available to monitor the effectiveness of rFVIIa.Given the small number of economic studies available and limitations in the reporting, methods, and generalizability of these studies, conclusions about the cost-effectiveness of using rFVIIa toprevent bleeding in a Canadian setting cannot be made. An informative primary economic evaluation might be more appropriate when consistent effectiveness evidence is available and preventive use of this treatment more commonplace. As a result, the cost-effectiveness of using rFVIIa in the prevention of bleeding unrelated to hemophilia remains unknown. If rFVIIa is usedpreventively on a wider scale by clinicians in the future, the potentially eligible population for this treatment is substantial.

Project Status: Completed

URL for project: http://www.cadth.ca/media/pdf/457B_Recombinant_Activated_Factor_VII_tr_e.pdf

Year Published: 2010

URL for published report: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/960

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)